Treatment of hairy-cell leukemia.
Hairy-cell leukemia is an unusual chronic lymphoid leukemia with distinctive clinical and pathological features. The management of this disorder has been revolutionized in the last decade with the discovery of the efficacy of alpha interferon and the inhibitors of adenosine metabolism, deoxycoformycin and chlorodeoxyadenosine. The best treatment protocol for hairy-cell leukemia has not yet been defined. Patients may still die from their disease, particularly in the early phases of treatment. Conversely, some patients appear not to require treatment and others respond well to splenectomy and need no further therapy. An individualized clinical approach is recommended, with a role for splenectomy in the patient with cytopenia and a relatively low number of hairy cells in the bone marrow. The first line drug treatment remains interferon alpha given for 12-18 months, following which the patient is observed for clinical relapse. Deoxycoformycin remains a useful experimental agent but cannot be recommended for routine clinical use until issues of long term toxicity are resolved. Chlorodeoxyadenosine is a very promising experimental drug, but confirmation of the early data in larger group trials is required. Similarly the adjunctive use of granulocyte colony stimulating factor appears useful, but will need further study in larger groups of patients. There is little or no role for alkylating agents or more intensive chemotherapy in the modern management of hairy-cell leukemia.
Lill
M C
MC
Department of Medicine, UCLA 90024.
Golde
D W
DW
D015762:2-Chloroadenosine / Q000031:analogs & derivatives / Q000627:therapeutic use; D000917:Antibody Formation; D000970:Antineoplastic Agents / Q000627:therapeutic use; D017338:Cladribine; D003131:Combined Modality Therapy; D003839:Deoxyadenosines / Q000627:therapeutic use; D005500:Follow-Up Studies; D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use; D006801:Humans; D007153:Immunologic Deficiency Syndromes / Q000139:chemically induced; D007155:Immunologic Factors / Q000627:therapeutic use; D007370:Interferon Type I / Q000276:immunology / Q000627:therapeutic use; D007943:Leukemia, Hairy Cell / Q000188:drug therapy / Q000601:surgery / Q000628:therapy*; D015649:Pentostatin / Q000627:therapeutic use; D012074:Remission Induction; D012189:Retrospective Studies; D013156:Splenectomy
D000970:Antineoplastic Agents; D003839:Deoxyadenosines; D007155:Immunologic Factors; D007370:Interferon Type I; D016179:Granulocyte Colony-Stimulating Factor; D015762:2-Chloroadenosine; D015649:Pentostatin; D017338:Cladribine